Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.71
NAS:CELG's Cash-to-Debt is ranked lower than
86% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:CELG: 0.71 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 5.81 Max: No Debt
Current: 0.71
Equity-to-Asset 0.28
NAS:CELG's Equity-to-Asset is ranked lower than
87% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CELG: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.76 Max: 0.98
Current: 0.28
-0.68
0.98
Debt-to-Equity 1.69
NAS:CELG's Debt-to-Equity is ranked lower than
93% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:CELG: 1.69 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.4 Max: 2.88
Current: 1.69
-4.28
2.88
Interest Coverage 7.40
NAS:CELG's Interest Coverage is ranked lower than
88% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CELG: 7.40 )
Ranked among companies with meaningful Interest Coverage only.
NAS:CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 27.63 Max: 428.04
Current: 7.4
6.33
428.04
Piotroski F-Score: 5
Altman Z-Score: 4.81
Beneish M-Score: -2.60
WACC vs ROIC
10.11%
25.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 30.84
NAS:CELG's Operating Margin % is ranked higher than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:CELG: 30.84 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 29 Max: 32.84
Current: 30.84
-64.94
32.84
Net Margin % 21.35
NAS:CELG's Net Margin % is ranked higher than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:CELG: 21.35 )
Ranked among companies with meaningful Net Margin % only.
NAS:CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 21.35
-68.02
28.88
ROE % 38.40
NAS:CELG's ROE % is ranked higher than
97% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:CELG: 38.40 )
Ranked among companies with meaningful ROE % only.
NAS:CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 24.32 Max: 33.02
Current: 38.4
-48.42
33.02
ROA % 9.26
NAS:CELG's ROA % is ranked higher than
89% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:CELG: 9.26 )
Ranked among companies with meaningful ROA % only.
NAS:CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 9.26
-38.07
15.8
ROC (Joel Greenblatt) % 234.76
NAS:CELG's ROC (Joel Greenblatt) % is ranked higher than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:CELG: 234.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 212.3
Current: 234.76
-421.4
212.3
3-Year Revenue Growth Rate 22.80
NAS:CELG's 3-Year Revenue Growth Rate is ranked higher than
76% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CELG: 22.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 22.8
-42.8
241.3
3-Year EBITDA Growth Rate 19.30
NAS:CELG's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:CELG: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 19.35 Max: 295.8
Current: 19.3
-34
295.8
3-Year EPS without NRI Growth Rate 14.00
NAS:CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:CELG: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 14.7 Max: 109.7
Current: 14
-60.8
109.7
GuruFocus has detected 3 Warning Signs with Celgene Corp $NAS:CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CELG's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CELG Guru Trades in Q3 2016

Paul Tudor Jones 2,500 sh (New)
Signature Select Canadian Fund 34,700 sh (New)
Steven Cohen 249,800 sh (+1078.30%)
Ray Dalio 35,700 sh (+389.04%)
Ronald Muhlenkamp 73,515 sh (+271.12%)
Jim Simons 1,225,638 sh (+117.68%)
Pioneer Investments 4,595,046 sh (+8.83%)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (+218.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Ken Heebner Sold Out
Ken Fisher 199,770 sh (-2.13%)
Julian Robertson 368,940 sh (-2.69%)
Joel Greenblatt 268,338 sh (-15.42%)
Mario Gabelli 15,888 sh (-41.13%)
» More
Q4 2016

CELG Guru Trades in Q4 2016

George Soros 3,500 sh (New)
Steven Cohen 646,900 sh (+158.97%)
Ken Fisher 203,488 sh (+1.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
Ray Dalio Sold Out
Ronald Muhlenkamp 72,688 sh (-1.12%)
Pioneer Investments 4,520,555 sh (-1.62%)
Paul Tudor Jones 2,100 sh (-16.00%)
Julian Robertson 298,740 sh (-19.03%)
Mario Gabelli 11,339 sh (-28.63%)
Jim Simons 751,338 sh (-38.70%)
Joel Greenblatt 119,987 sh (-55.29%)
» More
Q1 2017

CELG Guru Trades in Q1 2017

Jeremy Grantham 1,900 sh (New)
Stanley Druckenmiller 82,400 sh (New)
Ray Dalio 43,412 sh (New)
John Burbank 20,710 sh (New)
David Rolfe 192,000 sh (New)
Signature Select Canadian Fund 51,450 sh (+48.27%)
Joel Greenblatt 158,126 sh (+31.79%)
Pioneer Investments 5,231,139 sh (+15.72%)
Mario Gabelli 12,709 sh (+12.08%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
George Soros Sold Out
Ronald Muhlenkamp 72,493 sh (-0.27%)
Ken Fisher 201,869 sh (-0.80%)
Julian Robertson 286,340 sh (-4.15%)
Paul Tudor Jones 1,900 sh (-9.52%)
Steven Cohen 330,000 sh (-48.99%)
Jim Simons 132,138 sh (-82.41%)
» More
Q2 2017

CELG Guru Trades in Q2 2017

Caxton Associates 3,600 sh (New)
Lee Ainslie 19,150 sh (New)
Jim Simons 1,170,638 sh (+785.92%)
David Rolfe 799,402 sh (+316.36%)
Jeremy Grantham 3,000 sh (+57.89%)
Ken Fisher 263,929 sh (+30.74%)
Joel Greenblatt 168,817 sh (+6.76%)
Murray Stahl 8,155 sh (+1.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 72,418 sh (-0.10%)
Pioneer Investments 5,193,810 sh (-0.71%)
Julian Robertson 283,240 sh (-1.08%)
Ray Dalio 40,801 sh (-6.01%)
Mario Gabelli 10,529 sh (-17.15%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2017-06-30 Reduce -1.08%0.07%$114.41 - $134.31 $ 143.8918%283,240
Ken Fisher 2017-06-30 Add 30.74%0.01%$114.41 - $134.31 $ 143.8918%263,929
Joel Greenblatt 2017-06-30 Add 6.76%0.02%$114.41 - $134.31 $ 143.8918%168,817
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$114.41 - $134.31 $ 143.8918%72,418
Mario Gabelli 2017-06-30 Reduce -17.15%$114.41 - $134.31 $ 143.8918%10,529
Julian Robertson 2017-03-31 Reduce -4.15%0.26%$111.53 - $126.88 $ 143.8920%286,340
Ken Fisher 2017-03-31 Reduce -0.80%$111.53 - $126.88 $ 143.8920%201,869
Joel Greenblatt 2017-03-31 Add 31.79%0.06%$111.53 - $126.88 $ 143.8920%158,126
Ronald Muhlenkamp 2017-03-31 Reduce -0.27%0.01%$111.53 - $126.88 $ 143.8920%72,493
Mario Gabelli 2017-03-31 Add 12.08%$111.53 - $126.88 $ 143.8920%12,709
George Soros 2017-03-31 Sold Out 0.01%$111.53 - $126.88 $ 143.8920%0
Julian Robertson 2016-12-31 Reduce -19.03%1.73%$97.63 - $124.16 $ 143.8929%298,740
Ken Fisher 2016-12-31 Add 1.86%$97.63 - $124.16 $ 143.8929%203,488
Joel Greenblatt 2016-12-31 Reduce -55.29%0.2%$97.63 - $124.16 $ 143.8929%119,987
Ronald Muhlenkamp 2016-12-31 Reduce -1.12%0.03%$97.63 - $124.16 $ 143.8929%72,688
Mario Gabelli 2016-12-31 Reduce -28.63%$97.63 - $124.16 $ 143.8929%11,339
George Soros 2016-12-31 New Buy0.01%$97.63 - $124.16 $ 143.8929%3,500
Julian Robertson 2016-09-30 Reduce -2.69%0.32%$100.25 - $116.27 $ 143.8933%368,940
Joel Greenblatt 2016-09-30 Reduce -15.42%0.06%$100.25 - $116.27 $ 143.8933%268,338
Ken Fisher 2016-09-30 Reduce -2.13%$100.25 - $116.27 $ 143.8933%199,770
Ronald Muhlenkamp 2016-09-30 Add 271.12%2.12%$100.25 - $116.27 $ 143.8933%73,515
Mario Gabelli 2016-09-30 Reduce -41.13%0.01%$100.25 - $116.27 $ 143.8933%15,888
Ken Heebner 2016-09-30 Sold Out 0.09%$100.25 - $116.27 $ 143.8933%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GILD, NAS:AMGN, NAS:BIIB, NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:KITE, NAS:EXEL, NAS:SGEN, NAS:IONS, NAS:ALNY, NAS:TSRO, NAS:BLUE, NAS:BIVV, NAS:UTHR, NAS:NBIX, NAS:JUNO, NAS:TECH » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014.

Guru Investment Theses on Celgene Corp

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Opening Bell
InvestorsObserver releases covered-call reports for Amazon.com, Bristol-Myers Squibb, Celgene, PayPal Holdings Inc. and Twitter
Spiros Segalas Commentary on Celgene Guru stock highlight
Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector. Read more...
David Rolfe Gains 3 Holdings, Sells 2 Others in 1st Quarter Guru reports quarterly portfolio
Wedgewood Partners’ David Rolfe (Trades, Portfolio) gained three new holdings during the first quarter and sold two others. His new positions are Edwards Lifesciences Corp. (NYSE:EW), Celgene Corp. (NASDAQ:CELG) and Boeing Co. (NYSE:BA). Read more...
Celgene Subsidiary Invests in Jounce Therapeutics Company recently went public
Celgene Switzerland SA, a subsidiary of Celgene Corp. (NASDAQ:CELG) and 10% owner of Jounce Therapeutics Inc. (NASDAQ:JNCE), purchased 625,000 shares of the company on Feb. 2, according a filing with the SEC. Read more...
9 Stocks Ray Dalio Continues to Buy Holdings the guru increased in the 2nd and 3rd quarters
Ray Dalio (Trades, Portfolio) founded his Connecticut-based hedge fund, Bridgewater Associates, in 1975. In both the second quarter and third quarter, the guru increased his position in the following stocks: Read more...
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Determining when each ratio is more appropriate to use than the other
Introduction Read more...

Ratios

vs
industry
vs
history
PE Ratio 44.69
CELG's PE Ratio is ranked lower than
69% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CELG: 44.69 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 44.97 Max: 432.92
Current: 44.69
17.92
432.92
Forward PE Ratio 16.53
CELG's Forward PE Ratio is ranked higher than
61% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. CELG: 16.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 44.69
CELG's PE Ratio without NRI is ranked lower than
69% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. CELG: 44.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 44.9 Max: 351.75
Current: 44.69
17.82
351.75
Price-to-Owner-Earnings 39.63
CELG's Price-to-Owner-Earnings is ranked lower than
56% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. CELG: 39.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 39.42 Max: 922
Current: 39.63
15.44
922
PB Ratio 13.33
CELG's PB Ratio is ranked lower than
88% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CELG: 13.33 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.4 Max: 23.65
Current: 13.33
4.02
23.65
PS Ratio 9.52
CELG's PS Ratio is ranked higher than
57% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CELG: 9.52 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.37  Med: 9.53 Max: 27.97
Current: 9.52
5.37
27.97
Price-to-Free-Cash-Flow 27.74
CELG's Price-to-Free-Cash-Flow is ranked higher than
50% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. CELG: 27.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 32.48 Max: 2438.33
Current: 27.74
14.87
2438.33
Price-to-Operating-Cash-Flow 26.09
CELG's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. CELG: 26.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.85  Med: 30.34 Max: 1172.5
Current: 26.09
13.85
1172.5
EV-to-EBIT 34.14
CELG's EV-to-EBIT is ranked lower than
67% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CELG: 34.14 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 33.1 Max: 144.7
Current: 34.14
-28.6
144.7
EV-to-EBITDA 29.82
CELG's EV-to-EBITDA is ranked lower than
67% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CELG: 29.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 28.25 Max: 125.5
Current: 29.82
-31.4
125.5
EV-to-Revenue 9.57
CELG's EV-to-Revenue is ranked higher than
58% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CELG: 9.57 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 9.3 Max: 28.9
Current: 9.57
5.1
28.9
PEG Ratio 2.78
CELG's PEG Ratio is ranked lower than
64% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. CELG: 2.78 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.38  Med: 2.39 Max: 3.26
Current: 2.78
1.38
3.26
Shiller PE Ratio 98.45
CELG's Shiller PE Ratio is ranked lower than
75% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. CELG: 98.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 80.95  Med: 138 Max: 3211
Current: 98.45
80.95
3211
Current Ratio 4.05
CELG's Current Ratio is ranked higher than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CELG: 4.05 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.17 Max: 44.53
Current: 4.05
1.35
44.53
Quick Ratio 3.89
CELG's Quick Ratio is ranked higher than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CELG: 3.89 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 7.02 Max: 44.15
Current: 3.89
1.13
44.15
Days Inventory 416.19
CELG's Days Inventory is ranked lower than
91% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CELG: 416.19 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 104.34  Med: 244.42 Max: 392.21
Current: 416.19
104.34
392.21
Days Sales Outstanding 51.77
CELG's Days Sales Outstanding is ranked higher than
63% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CELG: 51.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 51.77
43.42
71.27
Days Payable 223.00
CELG's Days Payable is ranked higher than
83% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CELG: 223.00 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 139.99 Max: 209.22
Current: 223
61.81
209.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.54
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. CELG: 2.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.66  Med: 5.58 Max: 124
Current: 2.54
1.66
124
Price-to-Median-PS-Value 1.00
CELG's Price-to-Median-PS-Value is ranked higher than
53% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CELG: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 2.07 Max: 30
Current: 1
0.59
30
Price-to-Peter-Lynch-Fair-Value 2.63
CELG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. CELG: 2.63 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.8 Max: 5.1
Current: 2.63
0.36
5.1
Earnings Yield (Greenblatt) % 2.93
CELG's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CELG: 2.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 2.8 Max: 6.7
Current: 2.93
-7.5
6.7
Forward Rate of Return (Yacktman) % 19.36
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. CELG: 19.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.3 Max: 34.8
Current: 19.36
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $12,191.30
EPS (TTM) $ 3.22
Beta1.46
Short Percentage of Float1.15%
52-Week Range $96.93 - 144.59
Shares Outstanding (Mil)782.35

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 13,225 15,642 18,491 21,775
EPS ($) 6.77 8.36 9.82 11.44
EPS without NRI ($) 6.77 8.36 9.82 11.44
EPS Growth Rate
(Future 3Y To 5Y Estimate)
20.52%
Dividends per Share ($)
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Opening Bell Sep 06 2017 
InvestorsObserver releases covered-call reports for Amazon.com, Bristol-Myers Squibb, Celgene, PayPa Jul 27 2017 
Spiros Segalas Commentary on Celgene Jul 10 2017 
Spiros Segalas' Harbor Capital Appreciation Fund Managers' Commentary Jul 10 2017 
David Rolfe Gains 3 Holdings, Sells 2 Others in 1st Quarter May 16 2017 
Study These Gurus, but Don’t Buy Their Funds Apr 14 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Celgene Switzerland Invests in Jounce Therapeutics Feb 02 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
9 Stocks Ray Dalio Continues to Buy Dec 22 2016 

More From Other Websites
Oddly, Juno Therapeutics Is Jumping 11.3% Today Sep 22 2017
Juno Tenders $250M Follow-on Public Offering of Common Stock Sep 22 2017
3 Big Biotech Stocks to Buy This Fall Sep 22 2017
Better Buy: Celgene Corporation vs. Merck & Co., Inc. Sep 22 2017
See what the IHS Markit Score report has to say about Celgene Corp. Sep 21 2017
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene Sep 20 2017
3 Stocks That Put Coca-Cola's Returns to Shame Sep 20 2017
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Sep 19 2017
Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade Sep 19 2017
Apple Leads 7 Top Stocks Holding In Buy Range Sep 19 2017
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA Sep 18 2017
What Analysts Recommend for Novartis in September 2017 Sep 18 2017
RBC Capital's Marc Harris breaks down his best biotech pi... Sep 18 2017
Gilead Sciences: Is The Kite Deal Too Little, Too Late? Sep 18 2017
Don't Make This Huge Mistake With Celgene Sep 17 2017
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020? Sep 16 2017
Traders give their award-winning stock picks ahead of thi... Sep 15 2017
RBC Launches Biotech Sector Coverage Amid 'An Innovation Revolution' Sep 14 2017
Short Sellers Hike Bets in Major Biotechs Sep 13 2017
[$$] Celgene Launch to Lift BeiGene Sep 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}